WO2019047989A2 - CRYSTALLINE FORMS OF ACID (3α, 5β, 6α, 7α) -6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IQUE - Google Patents

CRYSTALLINE FORMS OF ACID (3α, 5β, 6α, 7α) -6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IQUE Download PDF

Info

Publication number
WO2019047989A2
WO2019047989A2 PCT/CZ2018/000040 CZ2018000040W WO2019047989A2 WO 2019047989 A2 WO2019047989 A2 WO 2019047989A2 CZ 2018000040 W CZ2018000040 W CZ 2018000040W WO 2019047989 A2 WO2019047989 A2 WO 2019047989A2
Authority
WO
WIPO (PCT)
Prior art keywords
obeticholic acid
crystalline form
acid
crystalline
temperature
Prior art date
Application number
PCT/CZ2018/000040
Other languages
English (en)
French (fr)
Other versions
WO2019047989A3 (en
Inventor
Marketa Slavikova
Josef Zezula
Josef Cerny
Ondrej Dammer
Michal Simek
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2019047989A2 publication Critical patent/WO2019047989A2/en
Publication of WO2019047989A3 publication Critical patent/WO2019047989A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention is based on crystalline forms of obeticholic acids (I), chemical name
  • Obeticholic acid is a semi-synthetic bile acid analog with an agonistic effect on the farnesoid X receptor (FXR). It is designed for the treatment of liver diseases, e.g. primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) or primary sclerosing cholangitis (PSC).
  • PBC primary biliary cirrhosis
  • NASH nonalcoholic steatohepatitis
  • PSC primary sclerosing cholangitis
  • Obeticholic acid was first mentioned in the patent application WO2002072598. ft was isolated via column chromatography, and no physicochemical characterization of the solid form was mentioned here. Two patent applications WO2006122977 and US20090062526 followed, dealing with a synthesis of obeticholic acid.
  • Crystalline form A of obeticholic acid was described in patent application WO2016107575. Crystalline forms 1-2 and 1-3 were described in patent application WO2017008773.
  • Solid forms I and II of obeticholic acid are also described in patent application CN105777836.
  • XRPD X-ray powder diffraction
  • NMR solid-state nuclear magnetic resonance
  • DSC thermoanalytical techniques
  • the subject of the invention comprises crystalline forms of obeticholic acid marked as J-l and J-2.
  • the subject of the invention comprises crystalline form J-l of obeticholic acid, showing characteristic reflections in a radiographic (X-ray) powder record using CuKa radiation: 6.3; 9.4; 12.2; 14.4; 16.5 and 19.0 ⁇ 0.2° 2-theta.
  • obeticholic acid crystalline form J-l is characterized with the following other reflections in an X-ray powder record: 4.3; 5.1; 7.5; 8.8; 10.3 and 11.8; ⁇ 0.2° 2-theta.
  • Another subject of the invention comprises crystalline form J-2 of obeticholic acid, showing characteristic reflections in a (X-ray) powder record using CuKa radiation: 6.3; 8.9; 10.8; 15.8; 16.5; 18.4 and 20.3 ⁇ 0.2° 2-theta.
  • obeticholic acid crystalline form J-2 is characterized with the following other reflections in an X-ray powder record: 3.1; 4.1; 12.4 and 18.4 ⁇ 0.2° 2-theta.
  • Fig. 1 XRPD record of crystalline form J-l of obeticholic acid
  • Fig. 2 DSC record of crystalline form J-l of obeticholic acid
  • Fig. 3 XRPD record of crystalline form J-2 of obeticholic acid
  • Fig. 4 DSC record of crystalline form J-2 of obeticholic acid
  • Form J-l crystallized surprisingly well from methylisobutylketone (MIBK), as well as from a mixture of «-butyl acetate (H-BUOAC) and acetonitrile (MeCN), whereas form J-2 was obtained from acetone and combinations of cyclopentylmethylether (CPME) or isopropyl acetate (i-PrOAc) with cyclohexane.
  • MIBK methylisobutylketone
  • H-BUOAC «-butyl acetate
  • MeCN acetonitrile
  • CPME cyclopentylmethylether
  • i-PrOAc isopropyl acetate
  • X-ray powder record of crystalline form J-1 of obeticholic acid is presented in Figure 1.
  • Characteristic diffractions using radiation CuKa are 6.3; 9.4; 12.2; 14.4; 16.5 and 19.0 ⁇ 0.2° 2-theta.
  • Form J-1 also shows the following characteristic reflections: 4.3; 5.1; 7.5; 8.8; 10.3 and 11.8; ⁇ 0.2° 2-theta.
  • Diffraction peaks with relative intensity higher than 1% are presented in Table 3.
  • DSC Differential scanning calorimetry
  • X-ray powder record of crystalline form J-2 of obeticholic acid is presented in Figure 3. Characteristic diffractions using radiation CuKa are 6.3; 8.9; 10.8; 15.8; 16.5 and 18.4 ⁇ 20.3° 0.2 2-theta. Form J-2 also shows the following characteristic reflections: 3.1; 4.1; 12.4 and 18.4 ⁇ 0.2° 2-theta. Diffraction peaks with relative intensity higher than 1% are presented in Table 4. Table 4: XRPD - characteristic diffraction peaks of form J-2
  • Crystalline form J-1 of obeticholic acid is prepared by dissolving obeticholic acid in a solvent which is methyl isobutyl ketone or a mixture of solvents which are n-butyl acetate and acetonitrile at an increased temperature from 50 °C to the boiling point of the solvent or the mixture of solvents and following cooling of fhe produced solution to a temperature ranging from -10 °C to 40 °C. Crystallized form J-1 is then isolated using known techniques.
  • Crystalline form J-2 of obeticholic acid is prepared by dissolving of obeticholic acid in a solvent which is cyclopentyl methyl ether, isopropyl acetate or acetone at an increased temperature from 60 °C to the boiling point of the solvent, or another solvent is added as an antisolvent, e.g. cyclohexane or n-heptane.
  • a solvent which is cyclopentyl methyl ether, isopropyl acetate or acetone
  • the produced solution is cooled to a temperature ranging from -10 °C to 40 °C. Crystallized form J-2 is then isolated using known techniques.
  • the amorphous form of obeticholic acid can be prepared from both forms, J-1 as well as J-2, through a procedure comprising the following steps:
  • the crystalline form of obeticholic acid can be advantageously converted in step a/ to ammonium or sodium salt.
  • step b/ hydrochloric acid or phosphoric acid is advantageously added.
  • Crystalline forms of obeticholic acid J-1 and J-2 according to the submitted invention can be used for preparation of obeticholic acid with chemical purity higher than 99.80% according to HPLC (High Performance Liquid Chromatography). Crystalline forms of obeticholic acid J-l and 3-2 according to the submitted invention can be subsequently used for preparation of a pharmaceutical composition.
  • Another subject of the invention is a pharmaceutical composition containing crystalline form J-l or crystalline form J-2 of obeticholic acid and at least one pharmaceutically acceptable excipient.
  • at least one pharmaceutically acceptable excipient is selected out of the group including lactose, microcrystalline cellulose, carboxymethyl starch sodium salt and magnesium stearate.
  • the pharmaceutical composition is in the form of tablet.
  • Obeticholic acid (1.5 g) was dissolved while boiling in methyl isobutyl ketone (10 ml), and the produced solution, while being stirred, was gradually cooled to a laboratory temperature of approx. 23 °C. Suspension was then stirred at that temperature for 24 hours. The crystalline product was isolated through filtration and dried via sucking of air on a frit for 24 hours. 0.75 g (50% yield) of crystalline form J-l of obeticholic acid was obhtained. XRPD in Fig. 1, melting point 92.5 °C, content of methyl isobutyl ketone 8.0% (determined by gas chromatography (GC)).
  • GC gas chromatography
  • Obeticholic acid (0.227 g) was dissolved while boiling in acetone (0.6 ml), and the produced solution, while being stirred, was gradually cooled to a laboratory temperature of approx. 23 °C. Thick suspension was then stirred at that temperature for 24 hours. The crystalline product was isolated through filtration and dried via sucking of air on a frit for 24 hours. 0.124 g (55% yield) of crystalline form J-2 was obtained.
  • Obeticholic acid (1.67 g) was, while boiling, dissolved in cyclopentyl methyl ether (10 ml), cooled to approx. 80 C, then cyclohexane was slowly added (10 ml) while the mixture was stirred. The produced solution was gradually cooled to the laboratory temperature of approx. 23 °C and the suspension was stirred at this temperature for 22 hours. The crystalline product was isolated through filtration and dried via sucking of air on a frit. 1.29 g of crystalline form J-2 of obeticholic acid was obtained (yield 77%). XRPD in Fig. 3, melting point 78.6 °C, content of cyclopentyl methylether 5.56%, cyclohexane 3.8% (GC).
  • Obeticholic acid (1.5 g) was, while boiling, dissolved in isopropyl acetate (5 ml), then cyclohexane was slowly added (10 ml) while the mixture was stirred. The produced solution was gradually cooled to the laboratory temperature of approx. 23 °C and the suspension was stirred at this temperature for 22 hours. The crystalline product was isolated through filtration and dried via sucking of air on a frit for 24 hours, and then in a vacuum drier at 50 °C/180 mbar for 3 days. 1.24 g (83% yield) of crystalline form J-2 of obeticholic acid was obtained. Content of isopropyl acetate 0.05%, cyclohexane 3.3% (GC).
  • Obeticholic acid (300 mg, HPLC 95.83%) was dissolved at 80 °C in methyl isobutyl ketone (0.5 ml), and the solution, while being stirred and slightly cooled to a temperature of approx. 60 °C, was inoculated with crystals of form J-l (approx. 5 mg) and left stirred to cool to a laboratory temperature of approx. 23 °C. Suspension was then stirred at that temperature for 16 hours. The crystalline product was isolated through filtration and dried via sucking of air on a frit for 2 hours, and then in a vacuum drier at 40 °C/200 mbar for 16 hours. Crystalline form J-l of obeticholic acid was obtained (246 mg, yield 82%) of HPLC purity 99.38%. XRPD in Fig. 1 , content of methyl isobutyl ketone 8.5% (GC).
  • Obeticholic acid (30 g, HPLC 99.54%, content of chenoxydeoxycholic acid 0.32%) was dissolved at 53 °C in a mixture of butyl acetate (45 ml) and acetonitrile (45 ml), and the solution was stirred at that temperature for 30 minutes. Then the solution was cooled to the temperature of 40 °C and stirred at that temperature for 1 hour. The produced suspension was then cooled slowly along 5 hours to the temperature of -10 °C, ant at that temperature it was stirred for 16 hours. The crystalline product was isolated through filtration and the obtained white crystals were dried in a vacuum drier at 40 °C/200 mbar for 16 hours. Crystalline form J-1 of obeticholic acid (27.35 g, yield 91.2%) of HPLC purity 99.74%, content of chenoxydeoxycholic acid 0.17%.
  • Obeticholic acid (form J-1, 3.0 g; 7.14 mmol; HPLC 99.48%) was stirred up in demineralized water (60 ml) and the suspension was heated to 40 °C. At that temperature, 25% aqueous solution of ammonium hydroxide (1.35 ml) was added and the produced solution was stirred for 40 minutes and filtered. The solution was cooled to a temperature of 5 °C and at that temperature diluted phosphoric acid was dripped in during 30 minutes (1 ml of 85% of phosphoric acid + 1.5 ml of demineralized water). The suspension was stirred for 2 hours while being cooled, than it was filtered and washed through with water (approx. 60 ml).
  • amorphous obeticholic acid was dried for 16 hours in a vacuum drier at 40 °C/180 mbar.
  • Amorphous obeticholic acid was obtained (2.874 g, yield 95.8%)of HPLC purity 99.91%, content of methyl isobutyl ketone 790 ppm (GC), content of water 4%.
  • Mobile phase A 1.0 ml of 70% wt perchloric acid dissolved in 1000 ml of water
  • mobile phase B acetonitrile, linear gradient according to the table below, flow-rate 0.7 ml/min,
  • Residual solvents were determined through gas chromatography (GC) according to the method Ph. Eur. 2.2.28.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
PCT/CZ2018/000040 2017-09-05 2018-08-31 CRYSTALLINE FORMS OF ACID (3α, 5β, 6α, 7α) -6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IQUE WO2019047989A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2017-34072U CZ31099U1 (cs) 2017-09-05 2017-09-05 Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CZPUV2017-34072 2017-09-05

Publications (2)

Publication Number Publication Date
WO2019047989A2 true WO2019047989A2 (en) 2019-03-14
WO2019047989A3 WO2019047989A3 (en) 2019-06-06

Family

ID=60084157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2018/000040 WO2019047989A2 (en) 2017-09-05 2018-08-31 CRYSTALLINE FORMS OF ACID (3α, 5β, 6α, 7α) -6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IQUE

Country Status (2)

Country Link
CZ (1) CZ31099U1 (cs)
WO (1) WO2019047989A2 (cs)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
EA201891491A1 (ru) * 2015-12-22 2018-11-30 Интерсепт Фармасьютикалз, Инк. Полиморфные кристаллические формы обетихолевой кислоты
CN107531744B (zh) * 2016-03-31 2020-03-13 江苏恒瑞医药股份有限公司 一种奥贝胆酸的新结晶形式及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation

Also Published As

Publication number Publication date
CZ31099U1 (cs) 2017-10-17
WO2019047989A3 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
WO2017008773A1 (en) Crystalline forms of obeticholic acid
US11149017B2 (en) Solid state forms of apalutamide
EP3344607B1 (en) Solid state forms of selexipag
WO2012061469A2 (en) Crystalline forms of pralatrexate
EP3218351B1 (en) A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
WO2018140377A1 (en) Solid state forms of rucaparib and of rucaparib salts
WO2020075199A1 (en) Polymorphic forms of vadadustat
US20250243223A1 (en) Solid state forms of ixazomib citrate
WO2017037608A1 (en) Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
KR20100022081A (ko) 결정성 로티고틴 염기 및 이의 제조 방법
TW201829420A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
US20180273499A1 (en) Salts and solid state forms of vortioxetine
WO2015078424A1 (en) Crystalline forms of vemurafenib
WO2019047989A2 (en) CRYSTALLINE FORMS OF ACID (3α, 5β, 6α, 7α) -6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IQUE
EA024202B1 (ru) Кристаллические полиморфы в, с и d 7-хлор-4-(пиперазин-1-ил)хинолина и способы их получения
EP4063351A1 (en) Preparation method of quinoline derivative compounds
EP2408798A1 (en) Polymorphs of fluticasone furoate and processes for preparation thereof
US10577340B1 (en) Beraprost-314d crystals and methods for preparation thereof
US20200407382A1 (en) Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
WO2016157136A1 (en) Crystalline forms of idelalisib
WO2008038143A2 (en) Novel solid forms of rimonabant and synthetic processes for their preparation
CN107840823B (zh) 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
WO2009027766A2 (en) New crystalline solid forms of o-desvenlafaxine base
EP3999495A1 (en) Improved process for preparing ozanimod
EP3372592A1 (en) Solid forms of lesinurad amine salts

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18845462

Country of ref document: EP

Kind code of ref document: A2